Type 1 Diabetes Mellitus — Pathogenesis and Management

• Genetic susceptibility and HLA association: Approximately 90% of T1DM patients carry HLA-DR3 and/or HLA-DR4 alleles, with the highest risk in those carrying both alleles (HLA-DR3/DR4 heterozygotes). The remaining 10% are accounted for by other susceptibility loci (PTPN22, INS, CTLA4, IL2RA). Conversely, certain HLA alleles (HLA-DQ2) are protective. The genetic contribution explains only 50-60% of disease risk, indicating strong environmental triggers. The HLA association reflects major histocompatibility complex (MHC) Class II presentation of β-cell autoantigens to autoreactive T cells, a fundamental mechanism in disease initiation.

• T-cell mediated autoimmunity and loss of immune tolerance: The disease begins with breakdown of central and peripheral immune tolerance, allowing autoreactive T lymphocytes to escape negative selection in the thymus or fail to be suppressed by regulatory T cells (Tregs) in the periphery. CD8+ cytotoxic T lymphocytes (CTLs) directly recognize and kill β-cells presenting processed autoantigens (GAD65, IA-2, insulin peptides) in the context of HLA Class I molecules. CD4+ T helper cells amplify this response by recognizing antigen-presenting cells (APCs) displaying β-cell antigens on HLA Class II. This cellular infiltration of the islets—termed insulitis—consists predominantly of CD8+ T cells, CD4+ T cells, B cells, and macrophages. The loss of immune tolerance is facilitated by defects in regulatory T cell function and reduced production of anti-inflammatory cytokines (IL-10, TGF-β).

• B-cell autoimmunity and the development of autoantibodies: Circulating autoantibodies against β-cell antigens typically precede clinical disease by months to years. The primary autoantibodies—anti-insulin (IAA), anti-GAD65 (glutamic acid decarboxylase 65), anti-IA-2 (islet antigen 2, a tyrosine phosphatase), and anti-ZnT8 (zinc transporter 8)—serve as serological markers of autoimmune β-cell destruction. The presence of two or more autoantibodies defines the pre-diabetic autoimmune state and confers >90% risk of progression to clinical diabetes within 10 years. Autoantibody development reflects aberrant B cell activation and loss of tolerance in germinal centers, with subsequent generation of pathogenic IgG antibodies. While autoantibodies contribute to disease through antibody-dependent cellular cytotoxicity (ADCC) and complement activation, cellular immunity (especially CD8+ T cells) is considered the primary mechanism of β-cell destruction.

• Environmental triggers and molecular mimicry: Viral infections (particularly enterovirus infections including coxsackieviruses and enteroviruses) are proposed as environmental triggers that initiate autoimmunity in genetically susceptible individuals through molecular mimicry—structural similarity between viral proteins and β-cell autoantigens. The viral protein-specific T cell response cross-reacts with β-cell antigens, breaching immune tolerance. Other proposed environmental factors include early cow's milk exposure (β-casein protein structural homology with β-cell GAD65), reduced microbial diversity in early childhood ("hygiene hypothesis"), vitamin D deficiency, and intestinal dysbiosis altering gut barrier function and antigen presentation. These environmental exposures likely occur during critical developmental windows when immune tolerance is being established.

• Progressive β-cell loss and the development of hyperglycemia: The autoimmune destruction of β-cells is chronic and progressive, with clinical disease manifest only after ~90% of functional β-cell mass is destroyed. The lag between initiation of autoimmunity (often years before diagnosis) and clinical presentation explains the prolonged pre-diabetic autoimmune state detectable by autoantibody screening. As β-cell mass decreases, fasting glucose rises first, followed by postprandial glucose elevation as first-phase insulin secretion is lost. Once hyperglycemia becomes significant (fasting glucose >126 mg/dL), clinical symptoms emerge due to osmotic effects and metabolic derangement. The rate of β-cell destruction varies among individuals, explaining heterogeneity in disease presentation (rapid onset in young children, slower progression in adults with latent autoimmune diabetes in adults [LADA]). The hyperglycemia itself may accelerate β-cell destruction through glucotoxicity (impaired β-cell glucose metabolism and increased oxidative stress) and osmotic stress.

• Metabolic consequences of absolute insulin deficiency: The complete or near-complete loss of endogenous insulin secretion results in absolute insulin deficiency, fundamentally different from T2DM where insulin resistance predominates. Without insulin's anabolic actions, lipolysis becomes unopposed, leading to massive increase in free fatty acid (FFA) mobilization from adipose tissue. Hepatic oxidation of FFAs generates excessive acetyl-CoA, driving ketogenesis and production of β-hydroxybutyrate and acetoacetate. Simultaneously, loss of insulin's inhibitory effect on hepatic glucose output combined with decreased peripheral glucose uptake causes severe hyperglycemia (often >250 mg/dL at diagnosis). The combination of hyperglycemia and ketonemia creates the milieu for diabetic ketoacidosis (DKA), characterized by metabolic acidosis (pH <7.3), elevated anion gap, and elevated serum and urinary ketones. The osmotic effects of hyperglycemia (glucose >250 mg/dL exceeds the renal threshold for reabsorption) lead to osmotic diuresis, causing severe dehydration, electrolyte depletion (particularly potassium and phosphate despite normal or high total body stores), and metabolic derangements. The absolute nature of insulin deficiency explains why T1DM patients are insulin-dependent from disease onset, unlike T2DM where oral agents may suffice initially.

• Autoimmune destruction of β-cells as primary mechanism: The pathogenic process in T1DM is fundamentally autoimmune, distinguished from T2DM by the presence of circulating autoantibodies and insulitis. The inheritance of high-risk HLA alleles (particularly HLA-DR3/DR4) confers genetic predisposition but is neither sufficient nor necessary for disease development, as demonstrated by discordance in monozygotic twins (40-50%). This distinguishes T1DM from the nearly 100% concordance seen in T2DM monozygotic twins. The autoimmune etiology is confirmed by detection of multiple circulating autoantibodies in 85-90% of newly diagnosed T1DM patients and the effectiveness of intensive immunosuppression in temporarily preserving β-cell function in early disease (demonstrated in the Type 1 Diabetes Trial Network studies).

• Genetic susceptibility loci beyond HLA: While HLA accounts for ~50% of the genetic heritability, numerous non-HLA susceptibility loci have been identified through genome-wide association studies (GWAS). The PTPN22 gene encodes a lymphoid protein phosphatase involved in T cell receptor signaling; the disease-associated R620W polymorphism impairs negative selection of autoreactive T cells. The INS gene locus (insulin gene itself on chromosome 11) influences insulin expression in the thymus, affecting thymic negative selection; shorter VNTR (variable number tandem repeat) sequences are associated with higher risk. CTLA4 (cytotoxic T-lymphocyte-associated protein 4) polymorphisms reduce co-stimulatory blockade of T cell activation. IL2RA (interleukin-2 receptor alpha) variants affect regulatory T cell development and function. The cumulative effect of these genetic variants accounts for the ~6% of general population risk of developing T1DM and explains why only 3-5% of first-degree relatives of T1DM patients develop disease, despite some sharing identical high-risk genotypes.

• Environmental triggers: viral infections and molecular mimicry: Epidemiological and molecular evidence supports enterovirus infection (particularly coxsackievirus B strains) as a major environmental trigger, with the mechanism being molecular mimicry—structural homology between viral capsid proteins and β-cell autoantigens. Animal models (virus-induced diabetes in mice) demonstrate that viral infections can breach immune tolerance through cross-reactive T cell and B cell responses. Likewise, infections with cytomegalovirus (CMV) and rotavirus have been implicated in epidemiological studies. The temporal relationship between viral infections and development of autoantibodies in genetically susceptible individuals supports this mechanism, though causality remains incompletely proven. Seasonal variation in T1DM incidence (higher in winter months in temperate climates) suggests a role for seasonal viruses.

• Dietary factors and early-life microbial exposure: Cow's milk exposure in infancy is associated with increased T1DM risk in some studies, with β-casein (A1 variant) cross-reacting with β-cell GAD65; this risk is potentially reduced by exclusive breastfeeding and delayed introduction of cow's milk-based formulas. However, other studies fail to confirm this association, indicating dietary factors are not primary determinants. Vitamin D deficiency correlates with increased T1DM risk; proposed mechanisms include impaired immune tolerance (vitamin D promotes Treg differentiation) and direct effects on pancreatic β-cells. The "hygiene hypothesis" posits that reduced microbial exposure in developed nations, particularly in early childhood, leads to altered immune development with skewing toward Th1/Th17 and away from Th2/Treg responses, increasing autoimmune disease risk. This is supported by higher T1DM incidence in developed countries and protective effects of early microbial exposures observed in animal models. Gut dysbiosis (alterations in microbial composition) has been documented in T1DM patients and may contribute to altered intestinal permeability, increased bacterial lipopolysaccharide (LPS) translocation, and enhanced Toll-like receptor signaling that drives autoreactive T cell activation.

• Pregnancy and perinatal factors: Maternal-fetal HLA incompatibility and gestational hyperglycemia have been associated with increased T1DM risk in offspring. Intrauterine infection (particularly enterovirus) has been proposed as a risk factor. Some evidence suggests that cesarean delivery (reducing microbial exposure during birth) and early antibiotic exposure may modestly increase risk, supporting the hygiene hypothesis. These factors have weaker evidence than genetic and viral triggers.

• Polyuria, polydipsia, and polyphagia as cardinal symptoms: Polyuria (excessive urination) results from osmotic diuresis when blood glucose exceeds the renal threshold (~180 mg/dL); glucose in the tubular fluid increases osmotic pressure, preventing water reabsorption and producing glucose-containing urine. Patients report nocturia, bed-wetting in children, and increased urinary frequency. Polydipsia (excessive thirst) is the physiological response to osmotic diuresis-induced dehydration and hypertonicity of extracellular fluid; osmoreceptors stimulate thirst through hypothalamic mechanisms. Patients may consume large volumes of fluids (including sugary drinks, paradoxically worsening hyperglycemia). Polyphagia (increased appetite) occurs despite weight loss due to loss of insulin's anabolic effects and increased catabolism; increased growth hormone and cortisol from stress and catabolism further drive appetite.

• Weight loss despite increased appetite as a distinctive feature: Unlike T2DM where patients are often overweight, weight loss is a hallmark of T1DM at presentation, reflecting loss of insulin's anabolic effects. Insulin normally promotes glucose uptake into muscle and adipose tissue and inhibits lipolysis; its absence leads to uncontrolled proteolysis and lipolysis. Patients may lose 5-10 kg over weeks to months before diagnosis. The combination of weight loss with increased appetite is particularly distinctive and should prompt consideration of T1DM.

• Fatigue and weakness: Patients report profound fatigue and weakness resulting from reduced glucose utilization by tissues (despite elevated blood glucose), impaired glycogen synthesis, and metabolic acidosis. These symptoms reflect the fundamental disconnect between systemic hyperglycemia and cellular glucose starvation due to insulin deficiency.

• Blurred vision: Osmotic cataracts develop acutely when sustained hyperglycemia (>200 mg/dL) increases glucose in the lens; glucose is converted to sorbitol by aldose reductase, which accumulates (sorbitol cannot cross cell membranes) and draws water into the lens by osmosis, causing swelling and refractive changes. Hyperglycemia also causes osmotic changes in the vitreous and retina, producing blurred vision without permanent changes initially. Vision typically improves with glycemic control, unlike sorbitol-related cataracts which may persist.

• Diabetic ketoacidosis (DKA) as presenting manifestation: In approximately 25-30% of T1DM cases, particularly in young children (<5 years), the disease presents explosively with DKA rather than gradual onset of hyperglycemic symptoms. DKA is characterized by the triad of hyperglycemia (>250 mg/dL), metabolic acidosis (pH <7.30), and ketonemia/ketonuria with elevated anion gap. Clinical manifestations include: (1) Kussmaul respiration—rapid, deep breathing attempting to compensate for metabolic acidosis by increasing CO₂ elimination; (2) "fruity" odor to breath—caused by acetone (volatile ketone body); (3) abdominal pain and nausea/vomiting—from acidosis and gastric irritation; (4) dehydration—from osmotic diuresis and vomiting, often severe; (5) altered mental status—from severe dehydration, electrolyte abnormalities, and acidosis, ranging from lethargy to obtundation to coma. DKA is a medical emergency requiring immediate hospitalization, insulin infusion, fluid resuscitation, and electrolyte monitoring. Mortality in children presenting with DKA is 0.15-0.3% in developed countries but up to 5-10% in developing nations.

• Recurrent vulvovaginal or urinary tract infections: Hyperglycemia impairs neutrophil function (decreased chemotaxis, phagocytosis, and oxidative burst), making infections more frequent and severe. Glucose in urine provides a growth medium for bacteria. Women may present with recurrent candida vulvovaginitis (candida thrives in high-glucose environments); men may have balanitis.

• Irritability and behavioral changes: Particularly in children, metabolic derangement and hyperglycemia can present with personality changes, school performance decline, or behavioral problems secondary to osmotic and metabolic effects on the central nervous system.

• Physical examination findings: Most patients appear well-nourished to thin without acute distress initially, unless presenting with DKA. In established disease, patients demonstrate evidence of dehydration (dry mucous membranes, decreased skin turgor, tachycardia). Patients with DKA show tachypnea/Kussmaul respiration, dehydration, and possible altered mental status. Candida lesions may be visible in genital regions in females. The absence of physical stigmata of complications distinguishes newly diagnosed T1DM from long-standing disease, where examination may reveal evidence of retinopathy, nephropathy, or neuropathy (see Complications).

• Fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L): This is the most straightforward diagnostic test and is highly sensitive and specific when confirmed on a second occasion. A single fasting glucose ≥126 mg/dL is diagnostic only in symptomatic patients with acute de

• Isotonic IV fluids first: volume resuscitation with normal saline restores perfusion and lowers glucose before any insulin is given; correcting hypovolemia also blunts counter-regulatory hormone drive.
• Check potassium before insulin: insulin drives K⁺ intracellularly. If serum K⁺ is below roughly 3.3 mEq/L, replete potassium first — giving insulin can precipitate fatal arrhythmia and respiratory muscle weakness.
• Continuous regular insulin infusion (0.1 U/kg/hr, typically without a bolus in children because of cerebral edema risk) suppresses lipolysis and ketogenesis.
• Add dextrose to fluids once glucose falls to ~200 mg/dL so the insulin infusion can continue until the anion gap closes — gap closure, not glucose normalization, is the endpoint.
• Bicarbonate is not routine; ADA reserves it for extreme acidemia (pH <6.9). Overlap subcutaneous basal insulin with the infusion for 1–2 hours before stopping it, or ketoacidosis recurs.

First-line maintenance therapy

• Basal–bolus insulin is mandatory and lifelong (absolute insulin deficiency). ADA recommends a long-acting basal analog (glargine or degludec) plus a rapid-acting prandial analog (lispro, aspart) dosed by carbohydrate counting and correction factor — or an insulin pump.
• Continuous glucose monitoring is recommended by ADA for essentially all patients on intensive insulin, with time-in-range and A1c targets individualized (generally <7% in most adults without disabling hypoglycemia).
• Glucagon (injectable or nasal) prescribed to every patient for severe hypoglycemia, plus documented sick-day rules — never omit basal insulin during illness.

Escalation and definitive options

• Automated insulin delivery (hybrid closed-loop) systems for recurrent hypoglycemia or unmet targets.
• Teplizumab, an anti-CD3 monoclonal antibody, delays progression from stage 2 to clinical stage 3 disease in antibody-positive relatives.
• Pancreas or islet transplantation is reserved for brittle disease with hypoglycemia unawareness, usually alongside kidney transplant.

Acute emergencies

• Diabetic ketoacidosis: unopposed lipolysis and hepatic ketogenesis from absolute insulin deficiency; signalled by high anion gap metabolic acidosis with ketonemia, Kussmaul respiration, and fruity breath. Often triggered by infection or missed insulin. Emergency.
• Cerebral edema during DKA treatment: predominantly pediatric; osmolar shifts from overly rapid fluid administration or rapid glucose correction. Signalled by headache, bradycardia with hypertension, recurrent vomiting, or declining mental status after biochemical improvement — treat with hypertonic saline or mannitol. Emergency.
• Severe hypoglycemia (treatment complication): excess exogenous insulin, missed meals, exercise, or alcohol (which blocks gluconeogenesis). Adrenergic symptoms then neuroglycopenia, seizure, coma. Emergency; give IV dextrose or glucagon.
• Hypokalemia during DKA therapy: insulin plus fluids shift and dilute potassium despite whole-body depletion; signalled by falling K⁺ and ECG changes.

Chronic microvascular disease (mechanism: hyperglycemia-driven advanced glycation end products, polyol/sorbitol flux, protein kinase C activation)

• Retinopathy: microaneurysms, dot-blot hemorrhages, then neovascularization. ADA advises dilated eye exam beginning about 5 years after T1DM diagnosis.
• Nephropathy: hyperfiltration then mesangial expansion and Kimmelstiel–Wilson nodules; signalled by persistently elevated urine albumin-to-creatinine ratio — treat with an ACE inhibitor or ARB per ADA/KDIGO.
• Neuropathy: distal symmetric stocking-glove sensory loss; autonomic forms cause gastroparesis, hypoglycemia unawareness, and orthostasis. Insensate foot ulceration is the classic downstream lesion.

Macrovascular and other

• Accelerated atherosclerosis: myocardial infarction may be silent from cardiac autonomic neuropathy; ADA recommends statin therapy based on age and risk.
• Lipohypertrophy at injection sites: repeated injection into one site causes erratic absorption and unexplained glycemic swings — rotate sites.
• Associated autoimmune disease: Hashimoto thyroiditis, celiac disease, primary adrenal insufficiency, vitiligo, pernicious anemia; ADA recommends thyroid and celiac screening after diagnosis. New unexplained hypoglycemia with hyperpigmentation suggests Addison disease.
• Growth failure and delayed puberty with chronically poor control (Mauriac syndrome).

• Weight loss with polyuria, polydipsia, and polyphagia in a lean child or adolescent is T1DM until proven otherwise. Low or undetectable C-peptide with positive anti-GAD65 / anti-IA-2 / anti-ZnT8 / IAA separates it from T2DM; C-peptide is the single best discriminator when the stem is ambiguous (obese teen, adult-onset LADA).
• In suspected DKA, the single best next step is IV isotonic fluids — not insulin. Then check potassium; hold insulin if K⁺ is below ~3.3 mEq/L. The commonest wrong answer is starting an insulin drip immediately.
• The endpoint of DKA therapy is closure of the anion gap, not a normal glucose. Add dextrose and keep the insulin running; overlap subcutaneous basal insulin before stopping the drip.
• Serum sodium is falsely low in hyperglycemia and serum potassium is falsely reassuring (acidosis shifts K⁺ out of cells despite total-body depletion). Correct the sodium; assume the potassium will fall.
• Beta-hydroxybutyrate, not the nitroprusside urine ketone test, is the accurate marker. The nitroprusside reaction detects acetoacetate only, so urine ketones can paradoxically rise as the patient improves.
• Headache, bradycardia with hypertension, or falling consciousness hours into DKA treatment in a child = cerebral edema. Give hypertonic saline or mannitol; do not attribute it to "improving slowly."
• Dawn phenomenon vs Somogyi effect: both give morning hyperglycemia. A 3 a.m. glucose that is normal-to-high (growth hormone/cortisol surge) means dawn — increase basal insulin. A low 3 a.m. glucose means rebound after nocturnal hypoglycemia — decrease evening insulin. Reflexively raising the bedtime dose is the trap.
• The association examiners love is polyglandular autoimmunity: T1DM plus Hashimoto thyroiditis, celiac disease, or Addison disease. Falling insulin requirements with new hypoglycemia and hyperpigmentation points to adrenal insufficiency.
• Never answer metformin, a sulfonylurea, or an SGLT2 inhibitor as monotherapy in T1DM — insulin is obligatory, and SGLT2 inhibitors risk euglycemic DKA.